Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
14.15
+0.07 (0.50%)
At close: Aug 26, 2026, 4:00 PM EDT
14.15
0.00 (0.00%)
After-hours: Aug 26, 2026, 4:10 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$543,817
Profits / Employee
-$526,917
Market Cap
412.12M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EyePoint | 214 |
| Rocket Pharmaceuticals | 202 |
| Foghorn Therapeutics | 106 |
| Century Therapeutics | 78 |
| Upstream Bio | 75 |
| Larimar Therapeutics | 71 |
| Lexeo Therapeutics | 63 |
| X4 Pharmaceuticals | 45 |
ENTA News
- 16 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 - Business Wire
- 16 days ago - Enanta Pharmaceuticals Earnings release: Q3 2026 - Filings
- 16 days ago - Enanta Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 2 months ago - Enanta announces European Commission approval of Maviret - TheFly
- 2 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - Business Wire
- 2 months ago - Enanta to advance zelicapavir into registrational Phase 2b/3 clinical trial - TheFly
- 2 months ago - Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
- 2 months ago - Enanta Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts